On November 12, 2021 Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, reported that it will present translational data from the Phase 1 SURPASS trial during the poster session at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting in Washington, D.C. (or virtual) (Abstract #373) from November 12-14, 2021 (Press release, Adaptimmune, NOV 12, 2021, View Source [SID1234595373]). In addition, the Company will present a data update from four patients treated in the radiation sub-study of the Phase 1 trial with afami-cel (Abstract #376).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The SURPASS data show that the addition of AKTi along with next-gen enhancements results in an improved and more potent SPEAR T-cell product," said Karen Miller, Adaptimmune’s Senior Vice President, Pipeline Research. "The data we continue to generate in the Phase 1 SURPASS trial shows promising responses for patients across multiple solid tumor indications. We will continue to explore more next-gen enhancements and manufacturing improvements, informed by our ongoing translational research, to deliver the best cell therapies we can for people with cancer."

Addition of AKTi during manufacturing results in improved phenotype and proliferative potential of SPEAR T-cells – attributes that may contribute to more sustained antitumor immune responses

In vitro analyses of manufactured product samples

ADP-A2M4CD8 SPEAR T-cells were manufactured with and without AKTi
Samples manufactured with AKTi expanded more effectively during manufacturing compared to samples without
Flow cytometry analyses of ADP-A2M4CD8 SPEAR T-cells demonstrated increased stem cell memory content of the transduced population in samples manufactured in the presence of AKTi compared to those manufactured without
This increased stem cell memory content may be beneficial in generating a more sustained immune response in patients
Further experiments were conducted to evaluate the impact of AKTi on SPEAR T-cell manufacturing: surplus pre-infusion apheresis material from patients in the Phase 1 trial of afami-cel trial was remanufactured into research-grade afami-cel with or without AKTi
In vitro functional analyses showed that manufacturing afami-cel SPEAR T-cells with AKTi can remodel gene expression in favor of improved proliferation or cytotoxicity
Post-infusion analyses

ADP-A2M4CD8 SPEAR T-cells manufactured with AKTi demonstrated higher median persistence in peripheral blood of patients in the Phase 1 SURPASS trial, by peak vector copy number and by peak percent recovery, compared to those manufactured without
Serum cytokine responses, measured in peripheral blood of patients who received product manufactured with AKTi (n=14) showed similar or greater induction of host immune response compared to those who received product without AKTi (n=6)
Radiation sub-study (closed to enrollment in July 2021) of the Phase 1 trial with afami-cel

As of December 27, 2020 (data cut-off), 4 patients received low-dose radiation and afami-cel
Overall response rate was 33%, 1 partial response (PR) (melanoma; reported in 2019) out of 3 evaluable patients
Disease control rate was 100%, 1 PR, 2 stable diseases (SD) (1 patient with ovarian and 1 patient with head and neck cancer) out of 3 evaluable patients
Serum cytokine profiles were consistent with afami-cel monotherapy, confirming no apparent impact of low-dose radiation on persistence and peripheral immune response.
There was greater detection of SPEAR T-cells in tumor biopsies when infusion followed low-dose radiation, compared to samples from patients who received afami-cel monotherapy in the Phase 1 trial